The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.
Standard
The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. / Phillips, Glenn A; Brunt, Van; David, L; Roychowdhury, Suraja M; Naber, Dieter; Naber, Dieter.
In: J CLIN PSYCHIAT, Vol. 67, No. 9, 9, 2006, p. 1397-1403.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.
AU - Phillips, Glenn A
AU - Brunt, Van
AU - David, L
AU - Roychowdhury, Suraja M
AU - Naber, Dieter
AU - Naber, Dieter
PY - 2006
Y1 - 2006
N2 - OBJECTIVE: To examine treatment-specific changes in health-related quality of life (QOL) among patients with schizophrenia and to assess the association between clinical and QOL improvement. METHOD: This post hoc analysis used the findings of a 28-week, randomized, multicenter trial of patients with schizophrenia (DSM-IV) treated with olanzapine (10-20 mg/day) or ziprasidone (80-160 mg/day). Data were collected from August 2001 to December 2002. Efficacy was measured using the Positive and Negative Syndrome Scale (PANSS). Quality of life was assessed with the generic health self-administered Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36) and the disease-specific expert-administered Heinrichs-Carpenter Quality of Life Scale (QLS). Mixed-effects-repeated-measures and last-observation-carried-forward approaches were used to assess the effects of treatment on QOL and the association of clinical outcomes to QOL outcomes. RESULTS: Olanzapine- and ziprasidone-treated patients demonstrated similar improvement from baseline to endpoint on the SF-36 and QLS. All correlations between changes in PANSS scores and the SF-36 were significant (p <.001), ranging from -0.159 to -0.400. All correlations between changes in PANSS scores and the QLS were significant (p <.0001), ranging from -0.286 to -0.603. The correlations between the 2 QOL measures were generally significant but small to moderate in magnitude. CONCLUSIONS: The results of this study indicate that, in patients with schizophrenia, olanzapine and ziprasidone treatment are associated with significant QOL and clinical improvements. Further, the significant correlation between change scores on the PANSS and QOL measures suggests that treatment-related clinical improvements are associated with improved health-related and disease-specific QOL. CLINICAL TRIALS REGISTRATION: ClinicalStudyResults.org identifier 2347.
AB - OBJECTIVE: To examine treatment-specific changes in health-related quality of life (QOL) among patients with schizophrenia and to assess the association between clinical and QOL improvement. METHOD: This post hoc analysis used the findings of a 28-week, randomized, multicenter trial of patients with schizophrenia (DSM-IV) treated with olanzapine (10-20 mg/day) or ziprasidone (80-160 mg/day). Data were collected from August 2001 to December 2002. Efficacy was measured using the Positive and Negative Syndrome Scale (PANSS). Quality of life was assessed with the generic health self-administered Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36) and the disease-specific expert-administered Heinrichs-Carpenter Quality of Life Scale (QLS). Mixed-effects-repeated-measures and last-observation-carried-forward approaches were used to assess the effects of treatment on QOL and the association of clinical outcomes to QOL outcomes. RESULTS: Olanzapine- and ziprasidone-treated patients demonstrated similar improvement from baseline to endpoint on the SF-36 and QLS. All correlations between changes in PANSS scores and the SF-36 were significant (p <.001), ranging from -0.159 to -0.400. All correlations between changes in PANSS scores and the QLS were significant (p <.0001), ranging from -0.286 to -0.603. The correlations between the 2 QOL measures were generally significant but small to moderate in magnitude. CONCLUSIONS: The results of this study indicate that, in patients with schizophrenia, olanzapine and ziprasidone treatment are associated with significant QOL and clinical improvements. Further, the significant correlation between change scores on the PANSS and QOL measures suggests that treatment-related clinical improvements are associated with improved health-related and disease-specific QOL. CLINICAL TRIALS REGISTRATION: ClinicalStudyResults.org identifier 2347.
M3 - SCORING: Zeitschriftenaufsatz
VL - 67
SP - 1397
EP - 1403
JO - J CLIN PSYCHIAT
JF - J CLIN PSYCHIAT
SN - 0160-6689
IS - 9
M1 - 9
ER -